Su­per­nus touts AD­HD Phase III da­ta, but re­sults ap­pear to fall short of ex­pec­ta­tions

CNS-fo­cused Su­per­nus Phar­ma­ceu­ti­cals $SUPN re­port­ed pos­i­tive da­ta from keen­ly watched twin stud­ies test­ing its non-stim­u­lant AD­HD drug in chil­dren on Thurs­day, but the re­sults sug­gest­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER